Medical cannabis use for the management of chronic pain is associated with an increased risk of new-onset arrhythmia, a Danish registry study has shown.
While the absolute risk difference remained low, the investigators flagged the need for caution and more research due to the increasing legalisation and use of medical cannabis worldwide.
The study, published in the European Heart Journal [link here], compared cardiovascular outcomes in 5,391 adults with chronic pain and a new claimed prescription for medical cannabis and 26,941 matched controls with a chronic pain diagnosis using other pain medication.
Medicinal cannabis included products containing either tetrahydrocannabinol (THC) or cannabidiol (CBD) or both in equal amounts (THC/CBD). The study period was 2018-2021 following the launch of Denmark’s trial program of prescribed medical cannabis for chronic pain on January 1, 2018.
Patients had a median age of 59 years and included those with musculoskeletal (46%), neurological (13%), cancer (11%), or unspecified pain (30%).
The study found double the risk of new-onset arrhythmia in patients exposed to medical cannabis compared to non-exposed patients within 180 days of follow-up (0.8% v 0.4%; aRR 2.07).
Most events in the cannabis-exposed group were atrial fibrillation/flutter (76%), followed by paroxysmal tachycardias (12%), and other arrhythmias (12%).
The association between medical cannabis use and new-onset arrhythmia was consistently similar across prespecified subgroups based on age, sex and cannabis product type.
High risk groups
“Patients with known cardiometabolic disease and patients with cancer were the subgroups associated with the highest absolute risk differences, which could reflect an elevated susceptibility to the proposed side effects of medical cannabis use,” the study authors said.
In supplementary analyses, there was no difference in the risk of acute coronary syndrome between cannabis-exposed and non-exposed patients (aRR 1.20) and no significant associations with risk of first-time stroke or heart failure.
“However, these findings should be explored further as larger sample sizes or longer follow-ups could yield different results—especially since the most common arrhythmia observed, atrial fibrillation, is closely linked to the risk of acute coronary syndrome, stroke, and heart failure.”